2 results
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize theā¦
Approved WMORecruiting
The objective of this study is, to detect potential uses of plasma biomarkers in primary care, by (a) To investigate if plasma biomarkers are associated with working diagnosis in primary care.(b) To ascertain if diagnosis and patient managementā¦